Literature DB >> 12801840

Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.

Wolfgang Kern1, Susanne Danhauser-Riedl, Richard Ratei, Susanne Schnittger, Claudia Schoch, Hans-Jochem Kolb, Wolf-Dieter Ludwig, Wolfgang Hiddemann, Torsten Haferlach.   

Abstract

BACKGROUND AND OBJECTIVES: Detection of minimal residual disease (MRD) by multiparameter flow cytometry is an emerging prognostic factor in patients with acute myeloid leukemia (AML). The present analysis aimed at improving the applicability of this approach to more patients with AML. DESIGN AND METHODS: Bone marrow samples from unselected patients with AML at diagnosis and from healthy volunteers were immunophenotyped applying triple-stainings of 31 antigens. Leukemia-associated immunophenotypes were defined by gating on populations displaying an aberrant or infrequent immunophenotype and by applying Boolean algebra. The combination of gates obtained was applied to list mode data files containing measurements of normal bone marrow samples. Dilution experiments of AML samples in normal bone marrow were performed to test the linearity of measurements.
RESULTS: At least one aberrant/infrequent immunophenotype was identified (median, 2; range, 1-5) in all of 68 analyzed AML patients. The median frequencies of cells displaying an aberrant/infrequent immunophenotype within normal bone marrow ranged from 0.00% to 1.20% (median, 0.07%). Limiting this analysis to only the most sensitive aberrant/infrequent immunophenotype per patient resulted in frequencies of cells displaying an aberrant/infrequent immunophenotype within normal bone marrow ranging from 0.00% to 0.43% (median, 0.05%). Serial dilution experiments confirmed the linearity of measurements (R>0.90 in all cases analyzed). INTERPRETATION AND
CONCLUSIONS: The application of multiparameter flow cytometry to identify cells displaying an aberrant/infrequent immunophenotype and to quantify MRD is feasible in unselected patients with AML.

Entities:  

Mesh:

Year:  2003        PMID: 12801840

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  14 in total

Review 1.  Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation.

Authors:  Xiaodong Mo; Xiaojun Huang
Journal:  Front Med       Date:  2013-07-20       Impact factor: 4.592

2.  Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML.

Authors:  C Anthias; F L Dignan; R Morilla; A Morilla; M E Ethell; M N Potter; B E Shaw
Journal:  Bone Marrow Transplant       Date:  2014-02-10       Impact factor: 5.483

Review 3.  New approaches for the detection of minimal residual disease in acute myeloid leukemia.

Authors:  Anna van Rhenen; Bijan Moshaver; Gert J Ossenkoppele; Gerrit Jan Schuurhuis
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 3.952

4.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.

Authors:  Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J Borowitz; Peter Dreger; Issa Khouri; Homer A Macapinlac; Homer Macapintac; Eduardo Olavarria; Jerald Radich; Wendy Stock; Julie M Vose; Daniel Weisdorf; Andre Willasch; Sergio Giralt; Michael R Bishop; Alan S Wayne
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-14       Impact factor: 5.742

5.  Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target.

Authors:  Yang Yang; Saradhi Mallampati; Baohua Sun; Jing Zhang; Sang-Bae Kim; Ju-Seog Lee; Yun Gong; Zhen Cai; Xiaoping Sun
Journal:  Cancer Lett       Date:  2013-01-16       Impact factor: 8.679

6.  Monitoring of acute myeloid leukemia by flow cytometry.

Authors:  Wolfgang Kern; Susanne Schnittger
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

7.  Cryopreserved NK cells in the treatment of haematological malignancies: preclinical study.

Authors:  Monika Holubova; Michaela Miklikova; Martin Leba; Daniel Georgiev; Pavel Jindra; Martin Caprnda; Rachele Ciccocioppo; Peter Kruzliak; Daniel Lysak
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-10       Impact factor: 4.553

8.  Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.

Authors:  T Köhnke; D Sauter; K Ringel; E Hoster; R P Laubender; M Hubmann; S K Bohlander; P M Kakadia; S Schneider; A Dufour; M-C Sauerland; W E Berdel; T Büchner; B Wörmann; J Braess; W Hiddemann; K Spiekermann; M Subklewe
Journal:  Leukemia       Date:  2014-06-10       Impact factor: 11.528

Review 9.  How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.

Authors:  Marie C Béné; Jaspal S Kaeda
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

10.  Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial.

Authors:  Giacomo Gianfaldoni; Francesco Mannelli; Tamara Intermesoli; Sara Bencini; Damiano Giupponi; Giorgio Farina; Ilaria Cutini; Maria Ida Bonetti; Arianna Masciulli; Ernesta Audisio; Dario Ferrero; Chiara Pavoni; Anna Maria Scattolin; Alberto Bosi; Alessandro Rambaldi; Renato Bassan
Journal:  Blood Adv       Date:  2020-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.